To safeguard human and environmental health in a cost effective manner, we must develop a mechanistic basis for predicting toxic risk and assessing environmental exposure. We will address aspects of these goals by developing an understanding of the biochemistry, regulation, and toxicological significance of hydrolytic pathways of metabolism. We have targeted two groups of enzymes both of which are induced by peroxisome proliferators and which add water to xenobiotics. Since the epoxide functionality is the reactive center of some of the most dangerous mutagens, carcinogens and toxins known, the cytosolic epoxide hydrolase (cEH) is targeted in objective I. Based on our recent isolation of the message and gene of the cEH, we will examine its regulation and subcellular targeting. Parallel approaches in photoaffinity labeling, amino acid modification, enzyme kinetics and site directed mutagenicity are being used to determine catalytic mechanism. This information will be used to design more effective substrates and inhibitors. All of the above technology will be used to test the hypothesis that the cEH has an endogenous role in the biosynthesis of diols and tetrahydrofuran diols of a variety of lipids including arachidonic acid. Similar approaches will be used to assess the in vitro and in vivo roles of cEH in ameliorating toxicity. Our second objective emphasizes the carboxylesterases which metabolize esters such as malathion, permethrin and a variety of pharmaceuticals. Similar techniques will be used. We will purify hepatic esterases using esterase specific affinity columns that we have designed based upon potent transition state mimics of the enzymes. Based on this work we will isolate cDNA and genomic clones as in objective I and use these to study the regulation of the enzymes. We are investigating the catalytic mechanism of esterases relying heavily on production of mutants in the baculovirus expression system. We are using a new class of spectral substrates yielding highly sensitive assays to monitor serum and tissue esterases following xenobiotic exposure. The above information will be used to extend our appreciation of the role of esterases in the metabolism on natural and man made toxins.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES002710-15
Application #
2153187
Study Section
Toxicology Subcommittee 2 (TOX)
Project Start
1980-12-01
Project End
1998-03-31
Budget Start
1995-07-01
Budget End
1996-06-30
Support Year
15
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California Davis
Department
Zoology
Type
Schools of Earth Sciences/Natur
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Tu, Ranran; Armstrong, Jillian; Lee, Kin Sing Stephen et al. (2018) Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Sci Rep 8:5279
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 450 publications